KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EPS (Basic): 2009-2025

Historic EPS (Basic) for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $1.49.

  • Halozyme Therapeutics' EPS (Basic) rose 37.96% to $1.49 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.89, marking a year-over-year increase of 59.28%. This contributed to the annual value of $3.50 for FY2024, which is 64.32% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' EPS (Basic) stood at $1.49, which was up 9.56% from $1.36 recorded in Q2 2025.
  • Halozyme Therapeutics' EPS (Basic)'s 5-year high stood at $1.53 during Q3 2021, with a 5-year trough of $0.16 in Q2 2022.
  • Over the past 3 years, Halozyme Therapeutics' median EPS (Basic) value was $0.73 (recorded in 2024), while the average stood at $0.86.
  • Per our database at Business Quant, Halozyme Therapeutics' EPS (Basic) skyrocketed by 600.00% in 2021 and then tumbled by 75.00% in 2022.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' EPS (Basic) stood at $0.47 in 2021, then declined by 8.51% to $0.43 in 2022, then skyrocketed by 51.16% to $0.65 in 2023, then spiked by 66.15% to $1.08 in 2024, then soared by 37.96% to $1.49 in 2025.
  • Its EPS (Basic) was $1.49 in Q3 2025, compared to $1.36 in Q2 2025 and $0.96 in Q1 2025.